Posted by Michael Wonder on 25 Mar 2016
Introducing a common CADTH recommendation framework and establishing a minimum period of 120 calendar days for advance notification of anticipated submissions and resubmissions for CADTH Common Drug Review and pan-Canadian Oncology Drug Review Programs
23 March 2016 - CADTH will be implementing changes to the CDR Procedures and pCODR Procedures that will require all manufacturers/submitters to provide a minimum 120 calendar days advance notification for anticipated submissions and resubmissions.
This requirement will apply to all CADTH Pre-submission Information Requirements Forms received on May 1, 2016 and onwards, and would pertain to all submissions and resubmissions filed on or after September 1, 2016. This procedural revision has been made to improve forecasting of the quantity and type of CDR and pCODR applications to be filed.
This, in turn, will help with better resource planning, including clinical expert recruitment, and budgeting for both programs. In addition, this revision will ensure that CADTH has reasonable time to work with the manufacturer/submitter to prepare them for the submission process.
For more details, go to: https://www.cadth.ca/cdr-update-118
